Compare ESP & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ESP | SKYE |
|---|---|---|
| Founded | 1928 | 2012 |
| Country | United States | United States |
| Employees | N/A | 9 |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.4M | 23.3M |
| IPO Year | 1995 | 2013 |
| Metric | ESP | SKYE |
|---|---|---|
| Price | $56.20 | $0.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $64.00 | $15.00 |
| AVG Volume (30 Days) | 12.4K | ★ 322.8K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.76% | N/A |
| EPS Growth | ★ 31.88 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $43,950,872.00 | N/A |
| Revenue This Year | $10.30 | N/A |
| Revenue Next Year | $10.00 | N/A |
| P/E Ratio | $32.43 | ★ N/A |
| Revenue Growth | ★ 13.46 | N/A |
| 52 Week Low | $24.85 | $0.57 |
| 52 Week High | $62.15 | $5.75 |
| Indicator | ESP | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 52.26 | 51.49 |
| Support Level | $52.83 | $0.68 |
| Resistance Level | $57.45 | $0.83 |
| Average True Range (ATR) | 2.36 | 0.04 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 78.84 | 83.33 |
Espey Manufacturing & Electronics Corp is a power electronics design and OEM manufacturing company delivering products for military and severe environment applications. Its products include power supplies, power converters, filters, power transformers, magnetic components, power distribution equipment, UPS systems, and antennas. The applications of these products include AC and DC locomotives, shipboard power, shipboard radar, airborne power, ground-based radar, and ground mobile power. Espey services include design and development to specification, build to specifications provided by the customer, build to print, design services, design studies, environmental testing services, metal fabrication, painting services, and development of automatic testing equipment.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.